Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ercros, S.A. (ECR.MC)
Barcelona, ES
Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.59% | +0.59% | +1.48% | +9.94% | +0.00% | +15.49% | -2.00% | +1.48% | +376.39% | -36.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-6.1% Q1'26: -15.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-353.9% Q1'26: -15.4% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-7.7% Q1'26: +14.7% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%-4.5% Q1'26: -6.5% (vs Q1'25)
-
ROIC Chemicals: +3.4%-6.8% Q1'26: -9.4% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+0.0% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×35.69× Q1'26: -53.62× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
618.27M
est: 609.32M (+1.5%)
|
602.54M
est: 620.12M (-2.8%)
|
685.97M
est: 632.53M (+8.4%)
|
669.78M
est: 687.40M (-2.6%)
|
568.80M
est: 568.10M (+0.1%)
|
772.32M
est: 720.20M (+7.2%)
|
998.53M
est: 1.04B (-3.6%)
|
725.29M
est: 809.00M (-10.3%)
|
667.42M
est: 730.70M (-8.7%)
|
626.82M
est: 685.80M (-8.6%)
|
662.80M
662.80M – 662.80M
-3.4% YoY
|
715.70M
715.70M – 715.70M
+8.0% YoY
|
808.90M
808.90M – 808.90M
+13.0% YoY
|
| EBITDA |
33.07M
est: 50.21M (-34.1%)
|
70.39M
est: 51.10M (+37.7%)
|
52.43M
est: 52.13M (+0.6%)
|
61.41M
est: 56.65M (+8.4%)
|
42.11M
est: 46.82M (-10.1%)
|
90.85M
est: 59.35M (+53.1%)
|
121.71M
est: 85.33M (+42.6%)
|
43.27M
est: 66.67M (-35.1%)
|
25.91M
est: 50.85M (-49.0%)
|
6.25M
est: 47.73M (-86.9%)
|
46.13M
46.13M – 46.13M
-3.4% YoY
|
49.81M
49.81M – 49.81M
+8.0% YoY
|
56.30M
56.30M – 56.30M
+13.0% YoY
|
| EBIT |
13.20M
est: 23.44M (-43.7%)
|
51.18M
est: 23.86M (+114.5%)
|
34.40M
est: 24.33M (+41.4%)
|
28.17M
est: 26.44M (+6.5%)
|
11.78M
est: 21.85M (-46.1%)
|
62.72M
est: 27.71M (+126.4%)
|
91.75M
est: 39.83M (+130.3%)
|
11.00M
est: 31.12M (-64.7%)
|
-5.55M
est: 18.52M (-129.9%)
|
-28.14M
est: 17.38M (-261.9%)
|
16.80M
16.80M – 16.80M
-3.4% YoY
|
18.14M
18.14M – 18.14M
+8.0% YoY
|
20.50M
20.50M – 20.50M
+13.0% YoY
|
| Net Income |
7.24M
est: 3.35M (+116.0%)
|
45.16M
est: 14.06M (+221.2%)
|
44.58M
est: 9.42M (+373.4%)
|
31.04M
est: 19.20M (+61.7%)
|
6.26M
est: 10.97M (-43.0%)
|
43.30M
est: 30.17M (+43.5%)
|
62.99M
est: 61.26M (+2.8%)
|
27.59M
est: 36.57M (-24.6%)
|
-11.66M
est: 3.66M (-418.7%)
|
-53.59M
est: -27.43M (-95.3%)
|
-30.18M
-30.18M – -30.18M
-10.0% YoY
|
-21.03M
-21.03M – -21.03M
+30.3% YoY
|
914.4K
914.4K – 914.4K
+104.3% YoY
|
| SGA |
45.36M
est: 41.08M (+10.4%)
|
90.98M
est: 41.81M (+117.6%)
|
42.68M
est: 42.64M (+0.1%)
|
42.28M
est: 46.34M (-8.8%)
|
42.11M
est: 38.30M (+9.9%)
|
131.00M
est: 48.56M (+169.8%)
|
64.05M
est: 69.81M (-8.3%)
|
10.09M
est: 54.54M (-81.5%)
|
10.28M
est: 66.54M (-84.6%)
|
120.50M
est: 62.45M (+93.0%)
|
60.36M
60.36M – 60.36M
-3.4% YoY
|
65.17M
65.17M – 65.17M
+8.0% YoY
|
73.66M
73.66M – 73.66M
+13.0% YoY
|
| EPS |
0.06
est: 0.04 (+73.2%)
|
0.40
est: 0.15 (+160.1%)
|
0.40
est: 0.10 (+288.3%)
|
0.29
est: 0.21 (+38.1%)
|
0.06
est: 0.12 (-49.2%)
|
0.43
est: 0.33 (+30.3%)
|
0.67
est: 0.67 (+0.0%)
|
0.29
est: 0.40 (-27.5%)
|
-0.13
est: 0.04 (-425.0%)
|
-0.59
est: -0.30 (-96.7%)
|
-0.33
-0.33 – -0.33
-10.0% YoY
|
-0.23
-0.23 – -0.23
+30.3% YoY
|
0.01
0.01 – 0.01
+104.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Antonio Zabalza Marti | Executive Chairman of the Board, President & CEO | 661.0K | male |
| Asunción Loste Madoz | Director of Legal Department | — | female |
| Daniel Ripley Soria | Non-Director Secretary | — | male |
| Imma Comella Pons | Director of Institutional Relations & Communications | — | female |
| Joao Maria Guimaraes Jose de Mello | CEO & Director | — | male |
| Joaquin Sanmartín Muñiz | Director of Human Resources | — | male |
| Josep Rovira Pujals | Director of Administration | — | male |
| Maria Chantal Coll d'arnaude | Director of Sustainable Development | — | female |
| Pedro Rodríguez Sánchez | Chief Financial Officer | — | male |
| Pere Kirchner Baliu | Council Secretary | — | male |
| Agustín Franco Blasco | Chief Operating Officer | — | male |
| Xavier Alvarez Garcia | Director of the Internal Audit Service | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ECR.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
